Floatz logo

Netupitant

Chemotherapy-induced Nausea and Vomiting

Instituto Brasileiro de Controle do CancerSmall moleculePhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

66 Active assets in the Chemotherapy-induced Nausea and Vomiting cohort.

Asset / SponsorPhaseRating
Palonosetron
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4A
DEXAMETHASONE
Instituto do Cancer do Estado de São Paulo
Phase 4A
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Docetaxel
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BB
HR20013
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Netupitant is also rated in:

Breast Cancer Patients Treated With T-DXdDormant
BBB
Indicative ·
75 / 100
View asset →
breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →
Olanzapine-contained Four-drug AntiemeticDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →